Thrive Capital Partners VII Growth, L.P. 的 Form 4/A 修正申報
修正Oscar Health, Inc.（OSCR），2021/9/28 申報
- 申報編號
- 0000899243-21-038101
- 申報時間
- 2021/9/28 18:30 ET
- 交易日
- 2021/9/9-9/13
- 申報延遲
- 19 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/9/13
這份申報列了 5 筆非衍生性交易。公開市場買進合計 $1,873 萬。交易後 19 天申報。
這份修正申報取代了 0000899243-21-035729（2021/9/13 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Thrive Capital Partners VII Growth, L.P.CIK 0001841736 | 持股 10% 以上大股東 |
| Claremount VII Associates, L.P.CIK 0001841808 | 持股 10% 以上大股東 |
| Thrive Partners VII GP, LLCCIK 0001877733 | 持股 10% 以上大股東 |
| Thrive Partners VII Growth GP, LLCCIK 0001877735 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/9/9 | Class A Common Stock | P買進取得 | +180,891 | $17.23F1 | +$3,117,077.53 | 3,024,780 | 間接 | |
| 2021/9/9 | Class A Common Stock | P買進取得 | +263,821 | $17.69F3 | +$4,666,571.38 | 3,288,601 | 間接 | |
| 2021/9/10 | Class A Common Stock | P買進取得 | +250,000 | $17.74F4 | +$4,435,900 | 3,538,601 | 間接 | |
| 2021/9/13 | Class A Common Stock | P買進取得 | +156,324 | $16.84F5 | +$2,632,621.22 | 3,694,925 | 間接 | |
| 2021/9/13 | Class A Common Stock | P買進取得 | +221,228 | $17.52F6 | +$3,874,830.54 | 3,916,153 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII.
表 I 有 1 筆交易的價格引用這則附註。
- F2
Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
- F3
Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII.
表 I 有 1 筆交易的價格引用這則附註。
- F6
Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII.
表 I 有 1 筆交易的價格引用這則附註。
備註
This Amendment on Form 4/A amends and restates the Form 4 filed by the Reporting Persons on September 13, 2021 to correct the price per share reported in the third row of Table I, Column 4.